ARCHIVED · 2 LEFT · 2 CENTER · 1 RIGHT · Aug 20, 1:18 AM
Headlines emphasize different aspects, from the 'experimental' nature of the vaccine to raising 'new treatment hope' or simply stating it 'shows promise'.
30-SECOND READ
WORDING GAP
5 sources · 3 bias buckets · Medium confidence
Different Spin. The left frames it as "Experimental melanoma vaccine shows promising results". The right frames it as "A vaccine for melanoma recurrence? Merck, Moderna say trial promising".
SOURCE MAP TIMELINE
Aug 19, 10:16 PM: KABC / ABC7 Los Angeles joined the source map.
Aug 19, 10:19 PM: Deseret News joined the source map.
Aug 19, 10:50 PM: Semafor joined the source map.
Aug 19, 11:21 PM: Globe and Mail joined the source map.
Now: Wording Gap is 35/99 and story health is live match · 5 sources · 3 buckets · comparable news format.
ARCHIVED SOURCES
Merck and Moderna announced Wednesday that a personalized m RNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.
An experimental melanoma vaccine could reduce the risk of the cancer returning or spreading for some high-risk patients. It's personalized for each patient and optimized using artificial in...
Moderna and Merck said on Wednesday that a personalized m RNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of c...
The vaccine is built on the m RNA platform that allowed Moderna to quickly roll out COVID-19 vaccines five years ago.
Merck and Moderna announced a phase 3 trial using an m RNA-based experimental vaccine delayed recurrence of melanoma in a study involving 1,137 high-risk patients. The interim study results...